ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

ANAB AnaptysBio Inc

26.58
0.24 (0.91%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
AnaptysBio Inc ANAB 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.24 0.91% 26.58 05:33:53
개장가 저가 고가 종가 전일 종가
26.76 25.64 27.02 26.58 26.34
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
24/04/202422:00PRNUSActym Therapeutics Appoints Thomas Smart as CEO
12/03/202405:41EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/03/202405:36EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
12/03/202405:19EDGAR2Form 8-K - Current report
29/02/202423:15GLOBEAnaptys to Present at TD Cowen’s 44th Annual Health Care..
15/02/202400:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202422:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/01/202423:15GLOBEAnaptys to Present at Guggenheim’s 6th Annual Biotechnology..
10/01/202409:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/01/202409:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202407:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202407:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202406:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202406:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202406:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202406:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202406:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202406:09EDGAR2Form 8-K - Current report
28/11/202306:17EDGAR2Form 8-K - Current report
28/11/202306:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
08/11/202306:15GLOBEAnaptys Named a BioSpace 2024 Best Places to Work Winner
03/11/202305:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202305:18EDGAR2Form 8-K - Current report
03/11/202305:15GLOBEAnaptys Announces Third Quarter 2023 Financial Results and..
01/11/202322:15GLOBEAnaptys Announces Participation in November Investor..
26/10/202305:43EDGAR2Form 8-K - Current report
11/10/202322:15GLOBEAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist..
10/10/202322:01EDGAR2Form 8-K - Current report
09/10/202321:43DJNAnaptys Sees Positive Trial Results for Imsidolimad..
09/10/202321:15GLOBEAnaptys to Provide Overview of Rosnilimab, a PD-1 Agonist,..
09/10/202321:00GLOBEAnaptys Announces Positive Top-Line Phase 3 Clinical Trial..
19/09/202307:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/09/202307:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/09/202307:09EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/09/202305:18EDGAR2Form 8-K - Current report
19/09/202305:15GLOBEAnaptysBio Announces Appointment of John Orwin as Chairman..
12/09/202322:15GLOBEAnaptysBio to Present at the Stifel 2023 Immunology and..
08/08/202305:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/08/202305:18EDGAR2Form 8-K - Current report
08/08/202305:15GLOBEAnaptysBio Announces Second Quarter 2023 Financial..
01/08/202303:27DJNAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy..
01/08/202302:34GLOBEAnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI..
31/05/202305:15GLOBEAnaptysBio Announces Participation in Upcoming Investor..
12/05/202305:15GLOBEAnaptysBio Announces First Quarter 2023 Financial Results..

최근 히스토리

Delayed Upgrade Clock